Co-transfection of dendritic cells with AFP and IL-2 genes enhances the induction of tumor antigen-specific antitumor immunity

Yang,Jing-Yue; Li,Xiao; Gao,Li; Teng,Zeng-Hui; Liu,Wen-Chao

doi:10.3892/etm.2012.635

Co-transfection of dendritic cells with AFP and IL-2 genes enhances the induction of tumor antigen-specific antitumor immunity

Authors:
- Jing-Yue Yang
- Xiao Li
- Li Gao
- Zeng-Hui Teng
- Wen-Chao Liu
View Affiliations

Affiliations: Department of Clinical Oncology, State Key Discipline of Cell Biology, Xijing Hospital, Fourth Military Medical University, Xian, Shaanxi 710032, P.R. China, Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Xian, Shaanxi 710032, P.R. China, Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xian, Shaanxi 710032, P.R. China, Department of Pharmacology, Faculty of Preclinical Medicine, Fourth Military Medical University, Xian, Shaanxi 710032, P.R. China
Published online on: July 6, 2012 https://doi.org/10.3892/etm.2012.635
Pages: 655-660

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Dendritic cells (DCs) are highly efficient, specialized antigen-presenting cells and DCs transfected with tumor-related antigens are regarded as promising vaccines in cancer immunotherapy. The aim of the present study was to investigate whether DCs co-transfected with the α-fetoprotein (AFP) and human interleukin-2 (IL-2) genes were able to induce stronger therapeutic antitumor immunity in transfected DCs. In this study, DCs from hepatocellular carcinoma (HCC) patients were co-transfected with the IL-2 gene and/or the AFP gene. The reverse transcription-PCR (RT-PCR) data revealed that the DCs transfected with the adenovirus AdAFP/IL-2 expressed AFP and IL-2. The DCs co-transfected with IL-2 and AFP (AFP/IL-2-DCs) enhanced the cytotoxicities of cytotoxic T lymphocytes (CTLs) and increased the production of IL-2 and interferon-γ significantly compared with their AFP-DC, green fluorescent protein (GFP)-DC, DC or phosphate‑buffered saline (PBS) counterparts. In vivo data suggested that immunization with AFP-DCs enhances antigen-specific antitumor efficacy more potently than immunization with IL-2-DCs or AFP-DCs. These findings provide a potential strategy to improve the efficacy of DC-based tumor vaccines.

View Figures

View References

1	Nakamoto Y and Kaneko S: Dendritic cell-based immunotherapy for hepatocellular carcinoma. Gan To Kagaku Ryoho. 37:413–416. 2010.(In Japanese).
2	Cohen S, Haimovich J and Hollander N: Dendritic cell-based therapeutic vaccination against myeloma: vaccine formulation determines efficacy against light chain myeloma. J Immunol. 182:1667–1673. 2009. View Article : Google Scholar
3	Di Nicola M, Carlo-Stella C, Anichini A, et al: Clinical protocol. Immunization of patients with malignant melanoma with autologous CD34⁺ cell-derived dendritic cells transduced ex vivo with a recombinant replication-deficient vaccinia vector encoding the human tyrosinase gene: a phase I trial. Hum Gene Ther. 14:1347–1360. 2003.PubMed/NCBI
4	Dubsky P, Ueno H, Piqueras B, et al: Human dendritic cell subsets for vaccination (Review). J Clin Immunol. 25:551–572. 2005. View Article : Google Scholar : PubMed/NCBI
5	Cao DY, Yang JY, Dou KF, Ma LY and Teng ZH: α-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-cell response from hepatocellular carcinoma patients in vitro. Hum Immunol. 68:334–341. 2007.
6	Lapteva N, Aldrich M, Weksberg D, et al: Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunity. J Immunother. 32:145–156. 2009. View Article : Google Scholar
7	Chen L, Tang XD, Yu ST, et al: Induction of anti-tumour immunity by dendritic cells transduced with hTERT recombinant adenovirus in mice. J Pathol. 217:685–692. 2009. View Article : Google Scholar : PubMed/NCBI
8	Buchsel PC and DeMeyer ES: Dendritic cells: Emerging roles in tumor immunotherapy (Review). Clin J Oncol Nurs. 10:629–640. 2006. View Article : Google Scholar : PubMed/NCBI
9	Butterfield LH, Ribas A, Potter DM and Economou JS: Spontaneous and vaccine induced AFP-specific T cell phenotypes in subjects with AFP-positive hepatocellular cancer. Cancer Immunol Immunother. 56:1931–1943. 2007. View Article : Google Scholar : PubMed/NCBI
10	Evdokimova VN and Butterfield LH: Alpha-fetoprotein and other tumour associated antigens for immunotherapy of hepatocellular cancer (Review). Expert Opin Biol Ther. 8:325–336. 2008. View Article : Google Scholar : PubMed/NCBI
11	Gardini A, Ercolani G, Riccobon A, et al: Adjuvant, adoptive immunotherapy with tumor infiltrating lymphocytes plus interleukin-2 after radical hepatic resection for colorectal liver metastases: 5-year analysis. J Surg Oncol. 87:46–52. 2004.
12	Dillman R, Schiltz P, DePriest C, et al: Tumor-infiltrating lymphocytes and interleukin-2: dose and schedules of administration in the treatment of metastatic cancer. Cancer Biother Radiopharm. 19:730–737. 2004. View Article : Google Scholar : PubMed/NCBI
13	Xian J, Yang H, Lin Y and Liu S: Combination nonviral murine interleukin 2 and interleukin 12 gene therapy and radiotherapy for head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 131:1079–1085. 2005. View Article : Google Scholar : PubMed/NCBI
14	Bray D, Yu SZ, Koprowski H II, Rhee J, Kumar S, Pericle F, Suntharalingam M, Van Echo DA, Li D and O’Malley BW Jr: Combination nonviral interleukin 2 gene therapy and external-beam radiation therapy for head and neck cancer. Arch Otolaryngol Head Neck Surg. 129:618–622. 2003. View Article : Google Scholar : PubMed/NCBI
15	Li D, Zeiders JW, Liu S, Guo M, Xu Y, Bishop JS and O’Malley BW Jr: Combination nonviral cytokine gene therapy for head and neck cancer. Laryngoscope. 111:815–820. 2001. View Article : Google Scholar : PubMed/NCBI
16	Kimura Y, Mizuno H, Satake K, Tahara H and Tsukuda M: Effects of combined therapy with interleukin 2 and interleukin 12 gene-transfected tumor vaccine for head and neck carcinoma. Arch Otolaryngol Head Neck Surg. 129:1181–1185. 2003. View Article : Google Scholar : PubMed/NCBI
17	O’Malley BW Jr, Li D, McQuone SJ and Ralston R: Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside. Laryngoscope. 115:391–404. 2005.PubMed/NCBI
18	Li D, Ronson B, Guo M, Liu S, Bishop JS, Van Echo DA and O’Malley BW Jr: Interleukin 2 gene transfer prevents NKG2D suppression and enhances antitumor efficacy in combination with cisplatin for head and neck squamous cell cancer. Cancer Res. 62:4023–4028. 2002.PubMed/NCBI
19	Ovali E, Dikmen T, Sonmez M, Yilmaz M, Unal A, Dalbasti T, et al: Active immunotherapy for cancer patients using tumor lysate pulsed dendritic cell vaccine: a safety study. J Exp Clin Cancer Res. 26:209–214. 2007.PubMed/NCBI
20	Figdor CG, de Vries IJ, Lesterhuis WJ and Melief CJ: Dendritic cell immunotherapy: mapping the way. Nat Med. 10:475–480. 2004. View Article : Google Scholar : PubMed/NCBI
21	Koya RC, Weber JS, Kasahara N, et al: Making dendritic cells from the inside out: Lentiviral vector-mediated gene delivery of granulocyte-macrophage colony-stimulating factor and interleukin 4 into CD14⁺ monocytes generates dendritic cells in vitro. Hum Gene Ther. 15:733–748. 2004. View Article : Google Scholar
22	Liu Y, Chiriva-Internati M, Grizzi F, et al: Rapid induction of cytotoxic T-cell response against cervical cancer cells by human papillomavirus type 16 E6 antigen gene delivery into human dendritic cells by an adeno-associated virus vector. Cancer Gene Ther. 8:948–957. 2001. View Article : Google Scholar
23	Asemissen AM and Brossart P: Vaccination strategies in patients with renal cell carcinoma. Cancer Immunol Immunother. 58:1169–1174. 2009. View Article : Google Scholar : PubMed/NCBI
24	Timares L, Douglas JT, Tillman BW, et al: Adenovirus-mediated gene delivery to dendritic cells. Methods Mol Biol. 246:139–154. 2004.PubMed/NCBI
25	Chiriva-Internati M, Liu Y, Salati E, et al: Efficient generation of cytotoxic T lymphocytes against cervical cancer cells by adeno-associated virus/human papillomavirus type 16 E7 antigen gene transduction into dendritic cells. Eur J Immunol. 32:30–38. 2002. View Article : Google Scholar
26	Motta I, André F, Lim A, et al: Cross-presentation by dendritic cells of tumor antigen expressed in apoptotic recombinant canarypox virus-infected dendritic cells. J Immunol. 167:1795–1802. 2001. View Article : Google Scholar
27	Diebold SS, Cotton M, Koch N and Zenke M: MHC class II presentation of endogenously expressed antigens by transfected dendritic cells. Gene Ther. 8:487–493. 2001. View Article : Google Scholar : PubMed/NCBI
28	Moll H: Antigen delivery by dendritic cells (Review). Int J Med Microbiol. 294:337–344. 2004. View Article : Google Scholar
29	Alisa A, Ives A, Pathan AA, et al: Analysis of CD4⁺ T-cell responses to a novel alpha-fetoprotein-derived epitope in hepatocellular carcinoma patients. Clin Cancer Res. 11:686–6694. 2005.
30	Mizukoshi E, Nakamoto Y, Tsuji H, et al: Identification of alpha-fetoprotein-derived peptides recognized by cytotoxic T lymphocytes in HLA-A24⁺ patients with hepatocellular carcinoma. Int J Cancer. 118:1194–1204. 2006. View Article : Google Scholar : PubMed/NCBI